

PEOPLE

Oread (Lawrence, KS) has named its chief operating officer **Jack L. Armstrong** president, replacing **David Kimbrell**, the former president, CEO, and chairman of the board of directors. Additionally, **Daniel Azarnoff** has been appointed chairman of the board. Mr. Kimbrell will continue to serve as a director.

IntraBiotics Pharmaceuticals (Mountain View, CA) has announced the election of **Fritz R. Bühler** to its board of directors. Dr. Bühler is vice chairman of International Biomedicine Management Partners, a private investment group based in Switzerland that recently led a private placement for IntraBiotics, raising \$23 million. He is also the former head of worldwide clinical research at F. Hoffmann-La Roche.

Maureen A. Costello has been named to the newly created position of director, pharmaceutical development of Copernicus Therapeutics (Cleveland, OH). She joins the company from SmithKline Beecham, where she served as manager of biochemistry and quality control.

Cantab Pharmaceuticals (Cambridge, UK) has announced the appointment of **Simon Duffy** to the position of nonexecutive chairman of the board. He replaces Sir John Collins, who is retiring after a three-year term. Mr. Duffy is currently group finance director and deputy chairman at EMI Group, and currently serves on the boards of Imperial Tobacco, HMV Media Group, and GWR Group.

Marc B. Garnick has joined the board of directors of Genome Therapeutics Corp. (Waltham, MA). Dr. Garnick is the executive vice president and chief medical officer for Praecis Pharmaceuticals, and is also a clinical professor of medicine at Harvard Medical School and at the Beth Israel Deaconess Medical Center. Also joining the board is **Norbert Riedel**, president of the recombinant strategic business unit for Baxter Hyland Immuno, a division of Baxter Healthcare. Dr. Riedel was previously head of global biotechnology for Hoechst Marion Roussel.

ArQule (Medford, MA) has announced the appointment of **Stephen Hill** as president and CEO, effective April 1. Dr. Hill, who will also serve as a member of ArQule's board of directors, was most recently head of global drug development at F. Hoffmann-La Roche. As CEO, he succeeds **Eric Gordon**.

Shaman Botanicals (S. San Francisco, CA) has announced the appointment of **Loren D. Israelsen** as interim CEO during the compa-

ny's initial phase. Mr. Israelsen is president of LDI Group, a dietary supplement industry consulting firm, and one of the drafters of the US Dietary Supplement Health and Education Act of 1994. Also, **Thomas Carlson**, currently senior director of ethnobiomedical field research at Shaman Pharmaceuticals, will join Shaman Botanicals as acting vice president of medical ethnobotany. Shaman Botanicals has exclusive access to the botanical library of tropical plants of Shaman Pharmaceuticals for identification and development as botanical nutritional supplements.

Alan Kessman has been named CEO of Vion Pharmaceuticals (New Haven, CT). Mr. Kessman is the former chairman, president and CEO of Executone Information Systems as well as a member of Vion's board. **John Spears**, formerly president and CEO, will remain as president of the company.

Daniel Kisner has been named CEO of Caliper Technologies (Palo Alto, CA). Dr. Kisner was most recently president and COO of Isis Pharmaceuticals.

Nicholas J. Schork has joined Genset (Paris) as head of its newly established department of epidemiology and biostatistics, based in La Jolla, California. Dr. Schork is an associate professor in the department of epidemiology and biostatistics at Case Western Reserve University.

Diversa (San Diego, CA) has named president and chief technology officer **Jay M. Short** to the additional post of CEO, replacing **Terrance J. Bruggeman**. Mr. Bruggeman has resigned to pursue other interests.

Bruce Stillman, director of the Cold Spring Harbor Laboratory, has been appointed as an officer in the general division of the Order of Australia. The appointment is made for distinguished service of a high degree to Australia or to humanity at large, and is similar to a British knighthood. Dr. Stillman, a native of Australia, came to Cold Spring Harbor Laboratory in 1979, and became director in 1994 when James D. Watson assumed the role of president.



James R. Tobin has been elected to the board of directors of PathoGenesis Corp. (Seattle, WA), increasing the board to 10 members. Most recently, he was CEO of Biogen from 1997 to 1998.

GATC 1/3 V